Allosteric ligand-driven smart nanoconjugates for mutation-selective EGFR targeting: A precision approach to...

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Targeted therapies like tyrosine kinase inhibitors (TKIs) revolutionized EGFR-driven cancer treatment, particularly non-small cell lung cancer (NSCLC).
• Acquired resistance mutations (T790M, C797S) in EGFR limit TKI efficacy by altering drug binding.
• Allosteric EGFR inhibition presents a promising alternative, targeting unique binding pockets for enhanced selectivity and reduced toxicity.

Purpose of the Study:

• To review the molecular mechanisms of allosteric EGFR inhibition.
• To discuss the engineering of nanoconjugate platforms for improved drug delivery and efficacy.
• To explore strategies for overcoming pharmacokinetic and stability limitations of allosteric inhibitors.

Main Methods:

• Systematic review of literature on allosteric EGFR inhibitors and nanocarrier systems.
• Discussion of molecular basis for allosteric inhibition and resistance mutations.
• Analysis of nanoconjugate design, including surface modification and payload co-delivery.

Main Results:

• Allosteric inhibition shows potent activity against resistant EGFR isoforms.
• Nanoconjugates improve targeted delivery, intracellular trafficking, and drug release of allosteric inhibitors.
• Co-delivery with siRNA or CRISPR-Cas9 amplifies pathway suppression and delays resistance.
• Surface modifications enhance circulation time and tumor accumulation.

Conclusions:

• Allosteric EGFR inhibition combined with nanoconjugates offers a potent strategy against resistant cancers.
• Nanotechnology platforms can overcome limitations of allosteric inhibitors, enhancing therapeutic potential.
• Further research into nanocarrier engineering, immunogenicity, scale-up, and regulatory aspects is crucial for clinical translation.